Integrated BioPharma Inc., of Hillside, N.J., appointed Eric Friedman senior vice president of administration and operations and CEO of the company's subsidiary Agrolabs Inc.

Isolagen Inc., of Exton, Pa., appointed Martin Schmieg senior vice president and chief financial officer.

Lifeline Therapeutics Inc., of Denver, appointed Jim Krejci to its board.

Lipomics Technologies Inc., of West Sacramento, Calif., appointed Peter Matlock vice president of commercial development.

MAP Pharmaceuticals Inc., of Mountain View, Calif., appointed Timothy Nelson president and CEO.

Marc Pharmaceuticals Inc., of Stamford, Conn., appointed Michael Palfreyman consultant and chief scientific and development adviser.

MaxCyte Inc., of Gaithersburg, Md., appointed Stanley Erck to its board, and Ronald Holtz chief financial officer.

MDS Inc., of Toronto, appointed Stephen DeFalco chief operating officer, and Trevor Hawkins chief science and technology officer.

Merck KGaA, of Darmstadt, Germany, nominated Walter Zywottek general partner and member of its executive board.

MicroIslet Inc., of San Diego, appointed John Hagenbuch and Bradley Geier to its board.

Momenta Pharmaceuticals Inc., of Cambridge, Mass., appointed Ganesh Venkataraman senior vice president, research, and Steven Brugger senior vice president, strategic business operations.

Nastech Pharmaceutical Co. Inc., of Bothell, Wash., appointed Susan Bayh and Alexander Cross to its board.

NitroMed Inc., of Lexington, Mass., appointed Frank Douglas to its board.

Novagali Pharma, of Evry, France, appointed Simon Benita, Penny Asbell, Christophe Baudouin, Francine Behar-Cohen, Patrick Couvreur, Jose-Alain Sahel and Kazuo Tsubota to its scientific advisory board.

OccuLogix Inc., of Toronto, appointed Gilbert Omenn and Adrienne Graves to its board.

Omeros Corp., of Seattle, appointed Wayne Gombotz vice president, pharmaceutical operations, and Clark Tedford vice president of research.

Orchid BioSciences Inc., of Princeton, N.J., appointed Raymond Land senior vice president and chief financial officer.

Ortec International Inc., of New York, retained the services of Michel Hermans to commercialize and further develop OrCel.

OSI Pharmaceuticals Inc., of Melville, N.Y., appointed Michael Atieh executive vice president and chief financial officer; Katharine Stevenson to its board and chairperson of its audit committee; Robert Van Nostrand senior vice president and chief compliance officer; Gabe Leung executive vice president and president of oncology; Anker Lundemose executive vice president and president of Prosidion; Robert Simon executive vice president of the pharmaceutical development and technical operations group; Pablo Cagnoni interim senior medical officer for oncology clinical development; Jonathan Rachman vice president of clinical development for the diabetes/obesity team; and Karsten Witt senior medical officer for drug safety.

Oxxon Therapeutics Inc., of Boston, appointed Mark Payton vice president of corporate development.